Positive allosteric modulation of metabotropic glutamate receptor 5; a novel approach for the treatment of schizophrenia and cognitive disorders

代谢型谷氨酸受体 5 的正变构调节；

• 批准号: nhmrc : 1013709
• 负责人: Dr Karen Gregory
• 金额: $ 23.23万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/positive-allosteric-modulation-cognitive-disorders/109743
• 关键词: Positive; allosteric; modulation; metabotropic; glutamate

The metabotropic glutamate receptor subtype 5 (mGluR5) has emerged as an exciting new target for the treatment of schizophrenia and cognitive disorders. We will investigate novel drug-binding sites on these receptors with the aim to discover new therapeutics. These studies also aim to definitively characterize mGluR5 activity following treatment with novel compounds to improve our understanding of the normal function of these important receptors.

代谢型谷氨酸受体亚型5（mGluR5）已成为治疗精神分裂症和认知障碍的一个令人兴奋的新靶点。我们将研究这些受体上的新型药物结合位点，旨在发现新的治疗方法。这些研究还旨在明确表征用新型化合物治疗后的mGluR5活性，以提高我们对这些重要受体正常功能的理解。